ACT Biotech Inc

ACT Biotech Inc is a San Francisco-based, privately held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs.[1][2] It was founded in 2008.[3]

The Company's clinical stage pipeline includes:

  • Telatinib, an oral kinase inhibitor for the first-line treatment of advanced gastric cancer. It has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA).[4] It has reported encouraging interim results from a phase II trial.[1]
  • ACTB1003, an oral kinase inhibitor that targets cancer cells through multiple modes of action. It inhibits cancer cell growth by targeting the FGF receptor family, which are mutated in a number of human cancer types. ACTB1003 also directly induces apoptosis by targeting kinases downstream of the PI3K pathway, all at low nanomolar concentrations.

Other pipeline products include an oral Aurora A and B kinase inhibitor at the pre-IND stage, and an ABL tyrosine kinase inhibitor targeting the T315I mutant enzyme in pre-clinical development.[5][6]

References
  1. "ACT BIOTECH Announces Positive Interim Phase 2 Results with Telatinib in First-line Gastric Cancer". 11 Oct 2010.
  2. "ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare". 7 May 2008. Archived from the original on 25 October 2016. Retrieved 23 January 2018.
  3. Leuty, Ron (February 19, 2013). "ACT Biotech co-founder Ali Fattaey makes tracks to Curis". San Francisco Business Times. Retrieved October 24, 2016.
  4. "ACT Biotech Receives Orphan Drug Designation for Telatinib, an Orally Available and Highly Selective Kinase Inhibitor, in". 2 June 2010.
  5. Jim Kling (1 April 2011). "ACT Biotech Inc". Medtech Insight. Retrieved 22 February 2023.
  6. "biotickr". biotickr. Retrieved 2022-10-23.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.